Bladder Cancer

>

Latest News

Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.
FDA Approves Mitomycin Solution in Low-Grade Intermediate-Risk NMIBC

June 12th 2025

Data from the phase 3 ENVISION trial support the FDA approval of the mitomycin solution for patients with recurrent, low-grade, intermediate-risk NMIBC.

Data from the ENVISION trial may support UGN-102 as a well-tolerated, efficacious treatment in non–muscle-invasive bladder cancer.
Robust Responses Occur With UGN-102 in Recurrent Intermediate-Risk NMIBC

June 11th 2025

Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC
Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC

June 3rd 2025

Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm
Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm

May 31st 2025

"Given the superior efficacy of [chemoimmunotherapy], it holds promise as a first-line neoadjuvant therapy for MIBC, providing greater benefits to patients," according to the study authors.
Chemoimmunotherapy Boosts Pathological Complete Responses in MIBC

May 24th 2025

More News


Site Logo

Overview of Phase I/II Pemetrexed Studies

November 2nd 2004

Pemetrexed (Alimta) is an antifolate that is effective in the inhibitionof multiple enzyme targets including thymidylate synthase,dihydrofolate reductase, and glycinamide ribonucleotide formyl transferase.The compound has been evaluated in several phase I trials, bothas single agent and in combination with other cytotoxic agents. Theinitial schedule selected for further investigation in phase II trials waspemetrexed 600 mg/m2 as a 10-minute infusion on day 1 every 21 days.During the subsequent phase II development, the dose of pemetrexedwas adjusted to 500 mg/m2 due to bone marrow and gastrointestinaltoxicities. The adjusted dose of pemetrexed was well tolerated throughoutthe late-phase drug development program. Preclinical evidencesuggests that pemetrexed has additive or synergistic activity when combinedwith many other clinically important anticancer agents, includinggemcitabine (Gemzar), fluorouracil, carboplatin (Paraplatin),oxaliplatin (Eloxatin), paclitaxel, and vinorelbine (Navelbine). Doselimitingtoxicities in these studies were primarily hematologic, and therewas no evidence of cumulative hematologic toxicity. During the drugdevelopment program it was discovered that supplementation with folicacid and vitamin B12 profoundly increased the tolerability ofpemetrexed. The studies discussed in this review demonstrate thatpemetrexed is well tolerated as a single agent and will be an importantcontribution to combination chemotherapy regimens.